Technologies gained one of their first solid footholds in the clinical care of cancer patients with adoption into the treatment paradigm of lung cancer, while researchers turned their eyes to proving utility in other niches.
There were fewer mergers and acquisitions in the omics space in 2017, breaking a two-year streak of growth — however, the deals themselves stayed fairly large.
The partners will use the GuardantOMNI assay, a 500-plus-gene liquid biopsy panel designed to accelerate clinical trials and targeted cancer therapy research.
The researchers found that most advanced EGFR-mutant lung cancer patients harbored changes in an average of two to three other oncogenes.
The results of the study could have implications for liquid biopsy developers that aim to pick out patients more likely to respond to immunotherapies.
Guardant is providing its Guardant 360 CDx test for a clinical trial of Merck's small molecule, c-Met kinase inhibitor called tepotinib.
Investigators studied 442 patients with CUP and found mutations that could inform a specific treatment decision in more than half of them.
Guardant is alleging that Foundation's advertising of its own products has harmed both Guardant and cancer patients.
The registry collects data on cancer genetics and aims to provide patients with access to quality NGS testing, among other things.
Guardant will provide its Guardant360 liquid biopsy cancer assay to Pfizer's oncology business unit for use in clinical trials.
In PLOS this week: Mycobacterium abscessus linked to gastric conditions, placental gene expression changes associated with preterm birth, and more.
The Guardian reports that UK universities are looking into ways to reduce labs' reliance on single-use plastics.
People with certain gene variants tend to not like vegetables, particularly bitter ones, CNN reports.
MIT's Technology Review reports on a company's genetic test that gauges an embryo's susceptibility to certain diseases.